(EAY 131-I MATCH): GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss
Description: 
GDC-0032 (taselisib) is a potent, selective inhibitor of Class I phosphoinositide 3-kinase (PI3K) alpha, delta, and gamma isoforms, with approximately 30-fold less inhibition of the p110 beta isoform. PI3K is a lipid kinase involved in tumor cell proliferation, survival, and migration upon activation by growth factor receptors and integrins. PI3K catalyzes the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), a second messenger involved in the phosphorylation of Akt and associated proteins in the Akt/mammalian target of rapamycin (mTOR) pathway. Activating and transforming mutations of the gene encoding the p110 alpha subunit of PI3K (PIK3CA) are commonly found in solid and hematological tumors
Study Number: 

NCG 275215 I

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02465060

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.